About GSK
OUR STRATEGY
GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
We aim to positively impact the health of 2.5 billion people by the end of 2030.
How our Research & Development approach is getting us ahead of disease
£5.5 billion
Invested in Research & Development in 2022
69
Vaccines and medicines that are currently in development
>20
Major new vaccines and medicines approved since mid 2017
Here are some of our key achievements in pursuing our purpose to get ahead of disease
Two million of our vaccines are administered every day, and 40% of the world’s children receive a GSK vaccine each year.
We are developing cancer medicines with life-changing potential for patients including ovarian cancer, endometrial cancer and multiple myeloma.
We are developing monoclonal antibodies to help treat different diseases. Monoclonal antibodies are laboratory-made proteins that work in a similar way to antibodies. Antibodies are found naturally in our blood and help us to fight infection.
Advancing medicine through Clinical Trials
Clinical trials are medical research performed in people, which involve healthy volunteers or patients. Most clinical trials investigate whether a medicine is safe and effective for the treatment of a disease or medical condition. Results from clinical trials can be used to make new medicines available for patients in the UK and worldwide.
Not all clinical trials test new medicines; some may help with our understanding of disease processes, which in turn helps development of new treatments.
Not all clinical trials test new medicines; some may help with our understanding of disease processes, which in turn helps development of new treatments.
Clinical trial phases
Phase I
These are small clinical trials, which focus on the safety of new medicines, often conducted in healthy volunteers.
Phase II
These are larger clinical trials conducted in patients and help confirm if the medicine will work in patients who have the intended disease. Several doses of the new medicine are often tested to help identify the right dose in patients.
Phase III
These are large clinical trials conducted in patients, where the safety and effectiveness of the new medicine is tested, and the right dose to treat the disease is confirmed.
About Clinical Unit Cambridge (CUC)
At the CUC we have been running clinical trials for over 20 years.
Innovation
We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
Research & Development Strategy
Our Research & Development strategy focuses on the science of the immune system, human genetics and advanced technologies.
Therapeutic areas
We focus on four therapeutic areas: infectious diseases, HIV, immunology/respiratory, and oncology.
About GSK
OUR STRATEGY
GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
We aim to positively impact the health of 2.5 billion people worldwide by the end of 2030.
How our Research & Development approach is getting us ahead of disease
£5.5 billion
Invested in Research & Development in 2022
69
Vaccines and medicines that are currently in development
>20
Major new vaccines and medicines approved since mid 2017
Here are some of our key achievements in pursuing our purpose to get ahead of disease
Two million of our vaccines are administered every day, and 40% of the world’s children receive a GSK vaccine each year.
We are developing cancer medicines with life-changing potential for patients including ovarian cancer, endometrial cancer and multiple myeloma.
We are developing monoclonal antibodies to help treat different diseases. Monoclonal antibodies are laboratory-made proteins that work in a similar way to antibodies. Antibodies are found naturally in our blood and help us to fight infection.
Advancing medicine through Clinical Trials
Clinical trials are medical research performed in people, which involve healthy volunteers or patients. Most clinical trials investigate whether a medicine is safe and effective for the treatment of a disease or medical condition. Results from clinical trials can be used to make new medicines available for patients in the UK and worldwide.
Not all clinical trials test new medicines; some may help with our understanding of disease processes, which in turn helps development of new treatments.
Not all clinical trials test new medicines; some may help with our understanding of disease processes, which in turn helps development of new treatments.
Clinical Trial Phases
Phase I
These are small clinical trials, which focus on the safety of new medicines, often conducted in healthy volunteers.
Phase II
These are larger clinical trials conducted in patients and help confirm if the medicine will work in patients who have the intended disease. Several doses of the new medicine are often tested to help identify the right dose in patients.
Phase III
These are large clinical trials conducted in patients, where the safety and effectiveness of the new medicine is tested, and the right dose to treat the disease is confirmed.
About Clinical Unit Cambridge (CUC)
At the CUC we have been running clinical trials for over 20 years.
Innovation
We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
Research & Development Strategy
Our Research & Development strategy focuses on the science of the immune system, human genetics and advanced technologies.
Therapeutic areas
We focus on four therapeutic areas: infectious diseases, HIV, immunology/respiratory, and oncology.
